Full Press Release Details
MeiraGTx Reports Third Quarter 2019 Financial Results
LONDON and NEW YORK, November 7, 2019 (GLOBE NEWSWIRE) MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically
integrated, clinical stage gene therapy company, today announced financial results for the quarter ended September 30, 2019 and provided an update on recent progress.
Over the course of the third quarter, we continued to advance our broad pipeline of investigational gene therapies, said Alexandria Forbes, Ph.D.,
president and CEO, MeiraGTx. In recent months, we have shared data from our first completed clinical trial with the medical community at the annual meetings of the Retina Society and the American Academy of Ophthalmology. Additionally, we
continue to make strategic investments to develop next-generation, best-in-class gene therapy technologies, including our recent initiative to build a second cGMP
manufacturing facility and to bring plasmid production in house.
Third Quarter 2019 Clinical Development Highlights
Phase 1/2 trial of AAV-RPE65 for RPE65-Associated Retinal Dystrophy: Data from the trial
were presented in September 2019 at the 52nd Annual Scientific Meeting of the Retina Society and in October 2019 at the American Academy of Ophthalmology Annual Meeting. These data demonstrated
that AAV-RPE65 improved functional vision, as assessed by vision-guided mobility maze, retinal function, as assessed by static perimetry, and several measures of central vision, including central retinal
sensitivity, visual acuity and contrast sensitivity.
Phase 1/2 AQUAx trial of AAV-AQP1 for Grade 2/3
Radiation-Induced Xerostomia: MeiraGTx initiated the open-label, multi-center, dose-finding Phase 1/2 trial in the third quarter of 2019 and is enrolling patients with radiation-induced Grade 2/3 xerostomia following treatment for head and neck
The Company s single center Phase 1 dose-finding study of AAV-AQP1 also continues to
enroll patients at the National Institutes of Health (NIH). Enrollment in the third dose escalation cohort was completed in the third quarter of 2019.
Janssen-partnered investigational gene therapies: MeiraGTx and Janssen Pharmaceuticals, Inc. (Janssen), part of the Janssen Pharmaceutical Companies of
Johnson & Johnson, continue to advance a portfolio of partnered gene therapies for the treatment of inherited retinal diseases, including the Company s ongoing Phase 1/2 studies of AAV-RPGR for X-linked retinitis pigmentosa (XLRP) and AAV-CNGB3 and AAV-CNGA3 for achromatopsia (ACHM).
For more information related to all of our clinical trials, please visit www.clinicaltrials.gov.
Third Quarter 2019 Corporate Highlights
Expanding manufacturing capabilities: In August 2019, MeiraGTx raised approximately $75 million of gross proceeds in a public offering of
approximately 3.2 million of its ordinary shares. The Company intends to use a portion of the proceeds of this offering to expand its manufacturing capabilities, including building a second cGMP viral vector manufacturing facility as well as a
cGMP plasmid production facility. MeiraGTx is completing feasibility studies for the second facility and expects to begin construction in 2020.
Third Quarter 2019 Financial Results
September 30, 2019, MeiraGTx had cash and cash equivalents of approximately $253.3 million. This capital will be sufficient to fund its operating expenses and capital expenditure requirements into 2022.
Comparison of Three Months Ended September 30, 2019 and 2018
General and administrative expenses were $9.9 million for the three months ended September 30, 2019, compared to $6.6 million for the three
months ended September 30, 2018. The increase of $3.3 million was primarily due to increases in payroll, insurance and rent expenses, consulting fees and share-based compensation.
Research and development expenses for the three months ended September 30, 2019 were $4.6 million, compared to $8.1 million for the three
months ended September 30, 2018. The decrease of $3.5 million was primarily due to an increase in research funding provided by our license and collaboration agreements with Janssen, which was partially offset by increases in costs related
to our clinical trials and to the manufacture of material for our clinical trials.
Foreign currency gain was $0.1 million for the three months ended
September 30, 2019 compared to a loss of $0.7 million for the three months ended September 30, 2018. The increase of $0.8 million was primarily due to a strengthening of the U.S. dollar against the pound sterling during the three
months ended September 30, 2019.
Net loss for the three months ended September 30, 2019 was $10.5 million, or $(0.30) basic and diluted
net loss per ordinary share, compared to a net loss of $15.4 million, or $(0.59) basic and diluted net loss per ordinary share for the three months ended September 30, 2018.
MeiraGTx ended the third quarter of 2019 with $253.3 million in cash and cash equivalents, compared to $88.5 million as of September 30, 2018.
MeiraGTx (Nasdaq: MGTX) is a vertically integrated, clinical stage gene therapy company with six programs in clinical development and a broad pipeline of
preclinical and research programs. MeiraGTx has core capabilities in viral vector design and optimization and gene therapy manufacturing, as well as a potentially transformative gene regulation technology. Led by an experienced management
team, MeiraGTx has taken a portfolio approach by licensing, acquiring and developing technologies that give depth across both product candidates and indications. MeiraGTx s initial focus is on three distinct areas of unmet medical
need: inherited retinal diseases, neurodegenerative diseases and severe forms of xerostomia and xerophthalmia. Though initially focusing on the eye, central nervous system and salivary gland, MeiraGTx intends to expand its focus in the
future to develop additional gene therapy treatments for patients suffering from a range of serious diseases.
For more information, please visit
Forward Looking Statement
press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered
forward-looking statements, including, without limitation, statements regarding our product candidate development and anticipated 2019 milestones regarding our pre-clinical and clinical data and reporting of
such data and the timing of results of data in connection with AAV-AQP1 for the treatment of patients with radiation-induced Grade 2/3 xerostomia, as well as statements that include the words
expect, intend, plan, believe, project, forecast, estimate, may, should, anticipate and similar statements of a future or
forward-looking nature. These forward-looking statements are based on management s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that
may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, our incurrence of
significant losses; any inability to achieve or maintain profitability, acquire additional capital, identify additional and develop existing product candidates, successfully execute strategic priorities, bring product candidates to market, expansion
of our manufacturing facilities and processes, successfully enroll patients in and complete clinical trials, accurately predict growth assumptions, recognize benefits of any orphan drug designations, retain key personnel or attract qualified
employees, or incur expected levels of operating expenses; failure of early data to predict eventual outcomes; failure to obtain FDA or other regulatory approval for product candidates within expected time frames or at all; the novel nature and
impact of negative public opinion of gene therapy; failure to comply with ongoing regulatory obligations; contamination or shortage of raw materials; changes in healthcare laws; risks associated with our international operations; significant
competition in the pharmaceutical and biotechnology industries; dependence on third parties; risks related to intellectual property; litigation risks; and the other important factors discussed under the caption Risk Factors in our
Report on Form 10-Q for the quarterly period ended September 30, 2019, as such factors may be updated from time to time in our other filings with the SEC, which are accessible on the
SEC s website at www.sec.gov. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent
management s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, unless required by law, we disclaim any obligation to do so, even if subsequent events cause
our views to change. Thus, one should not assume that our silence over time means that actual events are bearing out as expressed or implied in such forward-looking statements. These forward-looking statements should not be relied upon as
representing our views as of any date subsequent to the date of this press release.
MEIRAGTX HOLDINGS PLC AND SUBSIDIARIES CONDENSED
CONSOLIDATED BALANCE SHEETS
| September 30, | December 31, | |||||||
| 2019 | 2018 | |||||||
| (unaudited) | ||||||||
| ASSETS | ||||||||
| CURRENT ASSETS: | ||||||||
| Cash and cash equivalents | $ | 253,330,623 | $ | 68,080,175 | ||||
| Prepaid expenses | 6,248,981 | 1,937,785 | ||||||
| Other current assets | 11,509,144 | 4,634,105 | ||||||
| Total Current Assets | 271,088,748 | 74,652,065 | ||||||
| Right-of-use assets | 28,801,757 | |||||||
| Property and equipment, net | 16,899,147 | 22,014,237 | ||||||
| Security deposits | 839,149 | 105,085 | ||||||
| Restricted cash | 123,376 | 123,376 | ||||||
| TOTAL ASSETS | $ | 317,752,177 | $ | 96,894,763 | ||||
| LIABILITIES AND SHAREHOLDERS EQUITY | ||||||||
| CURRENT LIABILITIES: | ||||||||
| Accounts payable | $ | 3,798,441 | $ | 3,042,861 | ||||
| Accrued expenses | 9,346,895 | 11,991,697 | ||||||
| Lease obligations, current | 2,028,689 | 27,199 | ||||||
| Deferred revenue - related party, current | 24,115,777 | |||||||
| Other current liabilities | 437,053 | |||||||
| Total Current Liabilities | 39,289,802 | 15,498,810 | ||||||
| Deferred revenue - related party | 62,837,715 | |||||||
| Lease obligations | 20,600,077 | 7,097 | ||||||
| Deferred rent | 201,264 | |||||||
| Asset retirement obligations | 131,213 | 128,119 | ||||||
| TOTAL LIABILITIES | 122,858,807 | 15,835,290 | ||||||
| COMMITMENTS | ||||||||
| SHAREHOLDERS EQUITY: | ||||||||
| Ordinary Shares, $0.00003881 par value, 1,288,327,750 authorized 36,571,722 issued and outstanding at September 30, 2019 27,386,632 issued and outstanding at December 31, 2018 | 1,420 | 1,064 | ||||||
| Capital in excess of par value | 390,053,479 | 229,054,460 | ||||||
| Accumulated other comprehensive income | 2,393,372 | 293,666 | ||||||
| Accumulated deficit | (197,554,901 | ) | (148,289,717 | ) | ||||
| Total Shareholders Equity | 194,893,370 | 81,059,473 | ||||||
| TOTAL LIABILITIES AND SHAREHOLDERS EQUITY | $ | 317,752,177 | $ | 96,894,763 |
MEIRAGTX HOLDINGS PLC AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND
COMPREHENSIVE LOSS (unaudited)
| For the Three-Month Period Ended September 30, | For the Nine-Month Period Ended September 30, | |||||||||||||||
| 2019 | 2018 | 2019 | 2018 | |||||||||||||
| License revenue - related party | $ | 3,582,586 | $ | $ | 6,349,222 | $ | ||||||||||
| Operating expenses: | ||||||||||||||||
| General and administrative | $ | 9,874,810 | $ | 6,629,052 | $ | 31,811,456 | $ | 35,129,120 | ||||||||
| Research and development | 4,614,446 | 8,109,160 | 27,362,432 | 22,827,176 | ||||||||||||
| Total operating expenses | 14,489,256 | 14,738,212 | 59,173,888 | 57,956,296 | ||||||||||||
| Loss from operations | (10,906,670 | ) | (14,738,212 | ) | (52,824,666 | ) | (57,956,296 | ) | ||||||||
| Other non-operating income (expense): | ||||||||||||||||
| Foreign currency gain (loss) | 115,470 | (677,488 | ) | 3,117,047 | (2,425,488 | ) | ||||||||||
| Change in fair value of warrant liability | (1,514,775 | ) | ||||||||||||||
| Other income | 83,075 | |||||||||||||||
| Interest income | 959 | 264 | 40,686 | 50,926 | ||||||||||||
| Interest expense | (9,283 | ) | (9,508 | ) | (28,311 | ) | (46,571 | ) | ||||||||
| Loss before income taxes | (10,799,524 | ) | (15,424,944 | ) | (49,695,244 | ) | (61,809,129 | ) | ||||||||
| Benefit for income taxes | 338,670 | 430,060 | ||||||||||||||
| Net loss | (10,460,854 | ) | (15,424,944 | ) | (49,265,184 | ) | (61,809,129 | ) | ||||||||
| Other comprehensive income: | ||||||||||||||||
| Foreign currency translation, net of tax of $338,670 and $0 for the three-month periods ended September 30, 2019 and 2018, respectively and $430,060 and $0 for the nine-month periods ended September 30, 2019 and 2018, respectively | 1,653,507 | 508,758 | 2,099,706 | 1,730,000 | ||||||||||||
| Total comprehensive loss | $ | (8,807,347 | ) | $ | (14,916,186 | ) | $ | (47,165,478 | ) | $ | (60,079,129 | ) | ||||
| Net loss | $ | (10,460,854 | ) | $ | (15,424,944 | ) | $ | (49,265,184 | ) | $ | (61,809,129 | ) | ||||
| Accretion on convertible preferred C shares and warrants | (1,806,512 | ) | ||||||||||||||
| Adjusted net loss | $ | (10,460,854 | ) | $ | (15,424,944 | ) | $ | (49,265,184 | ) | $ | (63,615,641 | ) | ||||
| Basic and diluted adjusted net loss per ordinary share | $ | (0.30 | ) | $ | (0.59 | ) | $ | (1.53 | ) | $ | (3.89 | ) | ||||
| Weighted-average number of ordinary shares outstanding | 34,663,623 | 26,340,450 | 32,111,733 | 16,355,849 |